ReNeuron wants to renew damaged brain cells with stem cell therapy. Founded in 1997 by leading scientists at the London-based Institute of Psychiatry, the company is researching the feasibility of transplanting stem cells into patients with Parkinson's disease, Huntington's disease, type 1 diabetes, stroke, and other neurological disorders. ReNeuron also is studying the possible use of stem cells to treat brain tumors and in non-therapeutic areas with its ReNcell drug development platform. Investors include Merlin Ventures, a leading UK biotechnology investor.

K-V Pharmaceutical Company (KV) is a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets branded and generic/non-branded prescription pharmaceutical products. The Company has a range of dosage form capabilities, including tablets, capsules, creams, liquids and ointments. KV conducts its branded pharmaceutical operations through Ther-Rx Corporation (Ther-Rx) and its generic/non-branded pharmaceutical operations through ETHEX Corporation (ETHEX). Through Particle Dynamics, Inc. (PDI), the Company also develops, manufactures and markets value-added raw material products for the pharmaceutical, nutritional, personal care, food and other markets. The Company has developed a variety of drug delivery and formulation technologies, which are primarily focused in four principal areas: SITE RELEASE; tastemasking; oral controlled release, and oral quick dissolving tablets.

Adnexus Therapeutics, Inc. engages in the discovery, development, and commercialization of Adnectins biologics/medicines in the United States. The company’s product candidates include Angiocept/CT-322, an anti-angiogenesis agent for treating cancer that blocks the VEGFR-2 pathway; and other Adnectin therapies for the treatment of oncology, immunology, and cardiovascular diseases. Adnexus Therapeutics, Inc. was formerly known as Compound Therapeutics, Inc. and changed its name to Adnexus Therapeutics, Inc. in June 2006. The company was founded in 2002 and is headquartered in Waltham, Massachusetts. As of October 19, 2007, Adnexus Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Co.

Endocyte, Inc. company was founded in 1996 and is based in West Lafayette, Indiana. Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers.

Grifols, Inc. company provides products and services through three primary divisions: bioscience, diagnostic, and hospital. The bioscience division processes plasma from the company's collection centers into therapeutic derivative products such as coagulation factors and liver dialysis products. Its diagnostic division makes reagents and testing devices and instruments for laboratories, including blood bags, separators, incubators, and refrigerators. Grifols provides equipment, software, nutritional products, and IV preparations for hospitals and pharmacies through its hospital division. The company operates nationwide and is a subsidiary of Spain-based Grifols, S.A.

ALK is a global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. We are devoted to improving quality of life for people with allergies by developing pharmaceutical products that target the actual cause of allergy. ALK is the world leader in allergy vaccination (immunotherapy) – a unique treatment that induces a protective immune response which reduces and potentially halts the allergic reaction.

Cytokinetics, Incorporated company was founded in 1997 and is headquartered in South San Francisco, California. Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule drug therapeutics for the treatment of cardiovascular diseases and cancer. The company’s lead product includes CK-1827452, a cardiac muscle myosin activator, which is in Phase IIa clinical trials for the treatment of heart failure. Its products under development stage comprise Ispinesib, a kinesin spindle protein inhibitor that is in Phase I/II clinical trials for the treatment of metastatic breast cancer; SB-743921, which is in Phase I/II trials to treat patients with non-Hodgkin or Hodgkin lymphoma; and GSK-923295, centromere-associated protein E inhibitor, which is in Phase I clinical trials to treat patients with refractory solid tumors. The company’s products under preclinical stage consist of CK-2017357, a skeletal sarcomere activator for the treatment of diseases and conditions associated with muscle weakness or wasting; and smooth muscle myosin inhibitor for the treatment of pulmonary arterial hypertension, and diseases and medical conditions associated with bronchoconstriction. It has a strategic alliance with Amgen Inc. to discover, develop, and commercialize novel small-molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure, as well as with GlaxoSmithKline to develop GSK-923295.

Ligand Pharmaceuticals Incorporated company was founded in 1987. Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that focuses on drug discovery and early-stage development of pharmaceuticals that address critical unmet medical needs or that are more effective and/or safer than existing therapies, more convenient to administer and are cost effective. The Company has research and development collaborations for its product candidates with numerous pharmaceutical companies. These collaborations include ongoing clinical programs at Bristol-Myers Squibb (BMS), GlaxoSmithKline (GSK), Pfizer, Schering-Plough, Wyeth, Cephalon and Celgene. It receives royalty revenues from King Pharmaceuticals (King), and GSK. In February 2007, it completed the sale of its AVINZA product line to King. Through October 2008, it received a 15% royalty on AVINZA net sales. On December 23, 2008, it acquired all of the outstanding common shares of Pharmacopeia, Inc. In December 2009, Ligand Pharmaceuticals Incorporated acquired Neurogen Corporation.

IGI Laboratories, Inc. was founded in 1977 and is headquartered in Buena, New Jersey. IGI Laboratories, Inc. engages in the development, manufacture, filling, and packaging of topical, semi solid, and liquid products for pharmaceutical, cosmeceutical, and cosmetic companies. The company focuses on the commercialization of its licensed Novasome encapsulation technology for skin care/treatment products. It licenses the Novasome encapsulation technology from Novavax, Inc. for applications in animal pharmaceuticals, biologicals, and other animal health products; foods, food applications, nutrients, and flavorings; cosmetics, consumer products, and dermatological over-the-counter and prescription products; fragrances; and chemicals, including herbicides, insecticides, pesticides, paints and coatings, photographic chemicals, and other specialty chemicals, as well as the processes for making the same. The company was formerly known as IGI, Inc. and changed its name to IGI Laboratories, Inc. in May 2008.

NitroMed, Inc. company has developed a technique to enhance nitric oxide and add it to drugs to improve their efficiency. Nitric oxide is formed in the body and plays a role in relaxing blood vessels, making it harder for blood platelets to stick to blood vessel walls, and thereby reducing the obstructions that lead to stroke. Its sole product, BiDil, has FDA approval and is specifically indicated for heart disease in self-identified African-Americans, a group that suffers from the disease at a higher rate than other ethnicities. NitroMed was acquired by health care investment group Deerfield Capital Management in 2009.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.